Tuesday - May 6, 2025
FRAMINGHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, today announced the launch of a redesigned mobile app for its popular View Suite platform. The new DH View Suite mobile app provides sales and marketing professionals with on-demand access to vital data and intelligence, maximizing their efficiency and success in the field.
“In today's healthcare sales environment, access to on-demand information is the ultimate competitive advantage,” said Leah Shea, VP of Product at Definitive Healthcare. “The DH View Suite mobile app gives our customers the power to transform every moment into a productive opportunity, enabling them to be more prepared for meetings, capitalize on conference interactions, and ultimately allowing them to drive more revenue.”
DH View Suite provides sales and marketing teams with access to key information on healthcare professionals and organizations. Users can review details about executives, relevant news, and affiliations alongside metrics on clinical performance, finances, quality, and installed technologies. DH View Suite enables teams to:
The DH View Suite mobile app ensures sales representatives have the critical information they need at their fingertips, giving them access to target accounts while on the move. This allows for quick preparations for client visits and ensures productive meetings during industry tradeshows and conferences. With immediate access to insights, sales and marketing teams are better positioned to succeed in today's competitive healthcare market.
The DH View Suite mobile app complements the View Suite platform, providing a seamless user experience across devices. It’s available for download in the U.S. on Apple and Android devices at no additional cost to existing View Suite customers.
For more information about DH View Suite, visit definitivehc.com.
About Definitive Healthcare
At Definitive Healthcare, our mission is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS products and solutions create new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
For Definitive Healthcare Investors
This press release includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the “safe harbor” protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as “likely,” “will,” “should,” “may,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects” or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding the functionality, timing, or scope of our product and feature updates, and statements reflecting our expectations about our ability to execute on our strategic plans, achieve future growth and achieve our financial goals.
For discussion of factors that could impact our operational and financial results, refer to our SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the SEC website at www.sec.gov. Factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them.
All information in this press release speaks only as of the date on which it is made, and Definitive Healthcare assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein. The development, release and timing of any features or functionality described for our products remains at our sole discretion and is subject to change without notice or consultation. The information provided is for informational purposes only and is not a commitment, promise or legal obligation to deliver any product, feature, or functionality and should not be relied upon in making purchasing decisions or incorporated into any contract.
Media Contacts:
Bethany Swackhamer
bswackhamer@definitivehc.com
Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
Last Trade: | US$2.77 |
Daily Change: | -0.07 -2.46 |
Daily Volume: | 431,194 |
Market Cap: | US$319.990M |
February 27, 2025 February 25, 2025 November 07, 2024 October 10, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load